These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody].
    Author: Kon S.
    Journal: Gan To Kagaku Ryoho; 1988 May; 15(5):1685-92. PubMed ID: 3259417.
    Abstract:
    It has been over 15 years since Eisen first suggested that immunoglobulin idiotype could serve as a tumor-specific antigen. Over 10 years ago, Stevenson pointed out that B cell malignancies would be ideal targets for the idiotype-directed immune responses because these tumors retain the idiotype molecule on their cell surface rather than secreting it. Since that time a number of studies with animal models have shown that either passive or active immune manipulation directed at cell surface idiotypic determinants could have therapeutic effects on B cell malignancies. In this paper we will summarize and update the results of our clinical trials with anti-idiotype antibodies in patients with B cell malignancies. The results indicate that anti-idiotype antibodies can have profound effects on tumors, causing regressions in the majority of the patients treated. In addition, these studies have revealed that human B cell tumors are idiotypically heterogeneous due to extensive V-region somatic mutation.
    [Abstract] [Full Text] [Related] [New Search]